1. Home
  2. CTNM vs CMT Comparison

CTNM vs CMT Comparison

Compare CTNM & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • CMT
  • Stock Information
  • Founded
  • CTNM 2009
  • CMT 1996
  • Country
  • CTNM United States
  • CMT United States
  • Employees
  • CTNM N/A
  • CMT N/A
  • Industry
  • CTNM
  • CMT Electronic Components
  • Sector
  • CTNM
  • CMT Consumer Discretionary
  • Exchange
  • CTNM Nasdaq
  • CMT Nasdaq
  • Market Cap
  • CTNM 142.3M
  • CMT 147.1M
  • IPO Year
  • CTNM 2024
  • CMT N/A
  • Fundamental
  • Price
  • CTNM $5.77
  • CMT $17.40
  • Analyst Decision
  • CTNM Strong Buy
  • CMT
  • Analyst Count
  • CTNM 4
  • CMT 0
  • Target Price
  • CTNM $22.50
  • CMT N/A
  • AVG Volume (30 Days)
  • CTNM 366.4K
  • CMT 31.4K
  • Earning Date
  • CTNM 08-12-2025
  • CMT 08-05-2025
  • Dividend Yield
  • CTNM N/A
  • CMT N/A
  • EPS Growth
  • CTNM N/A
  • CMT N/A
  • EPS
  • CTNM N/A
  • CMT 1.33
  • Revenue
  • CTNM N/A
  • CMT $285,680,000.00
  • Revenue This Year
  • CTNM N/A
  • CMT $1.07
  • Revenue Next Year
  • CTNM N/A
  • CMT $1.65
  • P/E Ratio
  • CTNM N/A
  • CMT $13.11
  • Revenue Growth
  • CTNM N/A
  • CMT N/A
  • 52 Week Low
  • CTNM $3.35
  • CMT $12.25
  • 52 Week High
  • CTNM $21.58
  • CMT $19.20
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • CMT 58.90
  • Support Level
  • CTNM N/A
  • CMT $16.98
  • Resistance Level
  • CTNM N/A
  • CMT $17.54
  • Average True Range (ATR)
  • CTNM 0.00
  • CMT 0.39
  • MACD
  • CTNM 0.00
  • CMT 0.00
  • Stochastic Oscillator
  • CTNM 0.00
  • CMT 83.33

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About CMT Core Molding Technologies Inc

Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.

Share on Social Networks: